TrialNeoplasia (New York, N.Y.)2025

Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study.

Lu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.